Indaptus Therapeutics is trading at $2.87, up +5.09%, with biotech-sector strength a possible backdrop to the October 20 move. - The supplied sector data shows XBI up 2.10%. - No clear company-specific announcement explaining the October 20 move surfaced in the search; available evidence does not establish a direct catalyst for Indaptus Therapeutics.